Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00576342 | Patient Preference Study | PHASE3 | COMPLETED | 129 | — | — | Dec 1, 2007 | Jan 1, 2008 | Jul 11, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| AL-3862+timolol, then COSOPT | OTHER | AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later. |
| COSOPT, then AL-3862+timolol | OTHER | Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later. |
| Name | Type | Description |
|---|---|---|
| AL-3862+timolol ophthalmic suspension | DRUG | - |
| Dorzolamide+timolol ophthalmic solution | DRUG | - |
Inclusion Criteria: * Sign informed consent; * Diagnosis of glaucoma or ocular hypertension; * On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy); * IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular ...